Screening for Primary Aldosteronism in Hypertensive Patients in China
A Prospective Study of the Incidence and Outcomes of Primary Aldosteronism in Chinese Hypertensive Patients
Shanghai Jiao Tong University School of Medicine · NCT04020783
This study is trying to see how common primary aldosteronism is among people with high blood pressure in China and how it affects their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Shanghai Jiao Tong University School of Medicine (other) |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT04020783 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the incidence and outcomes of primary aldosteronism (PA) among hypertensive patients in China. It will collect and analyze data on the characteristics of patients suspected or confirmed to have PA, thereby enhancing awareness and screening for this condition. The study will follow a prospective, multi-center design, focusing on patients aged 18 and older with hypertension and elevated aldosterone-to-renin ratios. The goal is to improve diagnosis and treatment strategies for PA in the hypertensive population.
Who should consider this trial
Good fit: Ideal candidates for this study are hypertensive patients aged 18 and older with a suspected or confirmed diagnosis of primary aldosteronism.
Not a fit: Patients who do not have hypertension or those who are not eligible based on the study's exclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better identification and management of primary aldosteronism, potentially improving outcomes for hypertensive patients.
How similar studies have performed: Other studies have indicated the importance of screening for primary aldosteronism in hypertensive populations, suggesting that this approach has been successful in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility criteria 1. Age: more than or equal to 18 years old; 2. Hypertensive patients ; 3. ARR \> 40; 4. Informed consent; Exclusion criteria: Not eligible for inclusion or in situations considered unqualified for the study by the investigator.
Where this trial is running
Shanghai
- Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine — Shanghai, China (RECRUITING)
Study contacts
- Principal investigator: Jiguang Wang, MD, PhD — Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
- Study coordinator: Jiguang Wang, MD, PhD
- Email: jiguangw@163.com
- Phone: +86-21-64370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Primary Aldosteronism, Primary aldosteronism, Screening